GLP-1 weight loss drugs leave users low on key nutrients, study finds

GLP-1 weight loss drugs leave users low on key nutrients, study finds

This study assessed nutrient intake in adults using GLP-1 receptor agonists (GLP-1RAs) and found widespread deficiencies in essential vitamins and minerals. Despite appetite suppression and weight loss benefits, most participants exceeded fat intake recommendations and failed to meet protein and micronutrient needs.

Glucagon-Like Peptide-1 Receptor Agonists Use Does Not Increase the Risk for Acute Pancreatitis and Is Associated with Lower Complications in Patients with Type 2 Diabetes Who Develop Acute Pancreatitis: A Multi-Center Analysis

A retrospective cohort study was performed using population-based data from the TriNetX platform. T2DM patients receiving GLP-1 RAs drugs between January 1, 2015, and October 31, 2023 were included. [American Journal of Gastroenterology] Abstract

Tirzepatide Users See 20.2% Average Weight Loss in Obesity Management Trial

A recent trial indicates that tirzepatide demonstrates […]

Manufacturers Must Adapt to Growing GLP-1 and GIP/GLP-1 RA Markets

Current Landscape Overview Glucagon-like peptide-1 (GLP-1) receptor agonists (RAs) are an emerging drug class that are mostly indicated to improve glycemic control in patients with type 2 diabetes mellitus (T2D) and reduce body weight. For the GLP-1 RA products approved for glycemic control in T2D, some have expanded use to younger patients, and/or in additional at-risk comorbid adult populations. For branded products approved to reduce weight i…

expert reaction to systematic review and meta- analysis on GLP-1 receptor agonists and mental health

A systematic review published in JAMA Psychiatry looks at weight loss drugs (GLP-1 receptor agonists) and mental health.   Prof Stella Chan, Charlie Waller Chair in Evidence-based Psychological Treatment, University of Reading, said: “This is a robustly conducted systematic review and meta-analysis, reporting the encouraging findings that these drugs improve quality of life in patients with obesity and diabetes. While it is positive to note that…

The Grey Market of Weight Loss: How Compounded GLP-1 Medications Continue Despite FDA Crackdowns

It began as a solution to scarcity. When GLP-1 receptor agonists like Ozempic and Wegovy were first introduced, they quickly ignited a public health and media firestorm—praised for their effectiveness in treating type 2 diabetes and aiding substantial weight loss. As celebrities and social media influencers touted dramatic results, demand skyrocketed, leading to widespread shortages that left many patients—particularly those with metabolic disor…